EMA takes negative view on masitinib Ocaliva, Translarna out - BioWorld Online
| AB Stock | EUR 0.78 0.01 1.27% |
About 61% of AB Science's investor base is looking to short. The analysis of current outlook of investing in AB Science SA suggests that many traders are alarmed regarding AB Science's prospects. The current market sentiment, together with AB Science's historical and current headlines, can help investors time the market. In addition, many technical investors use AB Science SA stock news signals to limit their universe of possible portfolio assets.
AB Science |
EMA takes negative view on masitinib Ocaliva, Translarna out BioWorld Online
Read at news.google.com
 |
AB Science Fundamental Analysis
We analyze AB Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AB Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AB Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
AB Science is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
AB Science SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AB Science stock to make a market-neutral strategy. Peer analysis of AB Science could also be used in its relative valuation, which is a method of valuing AB Science by comparing valuation metrics with similar companies.
Peers
AB Science Related Equities
| NANO | Nanobiotix | 10.36 | ||||
| IPH | Innate Pharma | 8.82 | ||||
| GNFT | Genfit | 0.55 | ||||
| ADOC | Adocia | 0.44 |
Complementary Tools for AB Science Stock analysis
When running AB Science's price analysis, check to measure AB Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AB Science is operating at the current time. Most of AB Science's value examination focuses on studying past and present price action to predict the probability of AB Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AB Science's price. Additionally, you may evaluate how the addition of AB Science to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |